Comparative Pharmacology
Head-to-head clinical analysis: DYNABAC versus E MYCIN E.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DYNABAC versus E MYCIN E.
DYNABAC vs E-MYCIN E
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dirithromycin is a macrolide antibiotic that binds to the 50S subunit of the bacterial ribosome, specifically to the 23S rRNA, inhibiting peptide chain elongation by blocking the translocation step. It also interferes with the assembly of the 50S ribosomal subunit. This action is primarily bacteriostatic but can be bactericidal at higher concentrations.
Erythromycin binds to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis by blocking the translocation of peptide chains.
500 mg orally once daily or 250 mg orally twice daily; usual duration 5-14 days depending on infection
250-500 mg orally every 6 hours or 333-500 mg every 8 hours; maximum 4 g/day.
None Documented
None Documented
Terminal elimination half-life is 9–12 hours in adults with normal renal function; may extend to 20–30 hours in severe renal impairment (CrCl <30 mL/min).
Terminal elimination half-life is 1.5-3 hours in adults; prolonged to 4-6 hours in neonates and patients with hepatic impairment.
Approximately 65% of a dose is excreted unchanged in the urine via glomerular filtration and tubular secretion; about 15% is excreted unchanged in the bile; fecal elimination accounts for <5%.
Primarily excreted unchanged in urine (70-80%) via glomerular filtration and tubular secretion; 15-20% excreted in feces via biliary elimination.
Category C
Category C
Macrolide Antibiotic
Macrolide Antibiotic